FDA Recall D-0605-2024
Glenmark Pharmaceuticals Inc., USA · Mahwah, NJ
Class I — life-threatening Ongoing 714 days on record
Product
Potassium Chloride Extended-Release Capsules, USP, (750 mg) 10 mEq K, 500-count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd. Plot No. 2, Phase-2, Pharma Zone SEZ, Pithampur, Dist.-Dhar, Madhya Pradesh 454 775, India, Manufactured for: Glenmark Pharmaceuticals Inc, USA, Mahwah, NJ 07430. NDC 68462-357-05
Reason for recall
Failed Dissolution Specifications
Recall record
- Recall number
D-0605-2024- Classification
- Class I
- Status
- Ongoing
- Voluntary or mandated
- Voluntary: Firm initiated
- Firm notification
- Letter
- Distribution
- Nationwide
- Recall initiated
- 2024-05-30
- Classified by FDA Center
- 2024-07-17
- FDA published
- 2024-07-24
- Recalling firm
- Glenmark Pharmaceuticals Inc., USA
- Firm location
- Mahwah, NJ
Drug identification
- Brand name(s)
- POTASSIUM CHLORIDE
- Generic name(s)
- POTASSIUM CHLORIDE
- Manufacturer(s)
- Glenmark Pharmaceuticals Inc., USA
- NDC(s)
68462-357- Route(s)
- ORAL
Operational response
A Class I recall indicates a strong likelihood of serious adverse health consequence or death. Pull affected lots from active dispensing immediately. Segregate inventory in a marked, locked location pending destruction or return. If product has already been dispensed, identify affected patients and contact them by your standard recall-notification protocol.
For the official FDA enforcement record, see FDA's Recall Search.